Table 2.
Infectious diagnoses and microbiological characteristics of the study cohort (n = 400)
| Cefazolin (n = 38) | Ceftriaxone (n = 104) | Ertapenem (n = 128) | Oxacillin (n = 130) | P | |
|---|---|---|---|---|---|
| Infection diagnosis | |||||
| abscess | 6 (15.8) | 16 (15.4) | 33 (25.8) | 32 (24.6) | 0.16 |
| bacteraemia without endocarditis | 18 (47.4) | 32 (30.8) | 23 (18.0) | 37 (28.5) | 0.03 |
| endocarditis | 5 (13.2) | 14 (13.5) | 1 (0.8) | 15 (11.5) | 0.0001 |
| intra-abdominal infection | 4 (10.5) | 9 (8.7) | 30 (23.4) | 6 (4.6) | <0.0001 |
| Lyme disease | 0 (0) | 13 (12.5) | 0 (0) | 0 (0) | <0.0001 |
| osteomyelitis | 14 (36.8) | 13 (12.5) | 25 (19.5) | 36 (27.7) | 0.004 |
| pneumonia | 6 (15.8) | 9 (8.7) | 13 (10.2) | 4 (3.1) | 0.03 |
| prosthetic joint infection | 4 (10.5) | 9 (8.7) | 3 (2.3) | 23 (17.7) | 0.0003 |
| SSTI and wound infection | 2 (5.3) | 4 (3.8) | 14 (10.9) | 22 (16.9) | 0.0075 |
| urinary tract infection | 2 (5.3) | 16 (15.4) | 39 (30.5) | 6 (4.6) | <0.0001 |
| Microbiology | |||||
| Gram-positive | 35 (92.1) | 53 (51.0) | 50 (39.1) | 128 (98.5) | <0.0001 |
| MSSA | 33 (86.8) | 5 (4.8) | 12 (9.4) | 121 (93.1) | <0.0001 |
| Streptococcus | 2 (5.3) | 46 (44.2) | 24 (18.8) | 4 (3.1) | <0.0001 |
| Gram-negative | 4 (10.5) | 30 (28.8) | 84 (65.6) | 5 (3.8) | <0.0001 |
| ESBL | 0 (0) | 0 (0) | 29 (22.7) | 0 (0) | <0.0001 |
| not ESBL | 3 (7.9) | 23 (22.1) | 23 (18.0) | 3 (2.3) | <0.0001 |
| some resistance | 1 (2.6) | 2 (1.9) | 16 (12.5) | 0 (0) | <0.0001 |
| no susceptibility | 0 (0) | 5 (4.8) | 17 (13.3) | 2 (1.5) | 0.004 |
| C. difficile infection in OPAT | 1 (2.6) | 0 (0) | 4 (3.1) | 0 (0) | NA |
NA, not applicable due to small sample size.